Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 324 clinical trials
PRE-GAiN Bone Health Pilot Study

will be randomized 1:1 into 2 groups. One group will receive treatment with a transdermal estrogen patch and the other group will not.

estrogen
estrogen replacement therapy
  • 12 views
  • 27 May, 2021
  • 1 location
Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma

Basal like breast carcinoma is a Her2, estrogen receptor (ER) progesterone receptor (PR) negative breast cancer. It is notable for the high level of epidermal growth factor receptor (EGFR

breast carcinoma
estrogen receptor
carcinoma
paclitaxel
cancer
  • 2 views
  • 07 Nov, 2020
  • 1 location
Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The secondary objectives are to evaluate:

  • 38 views
  • 28 Mar, 2021
  • 56 locations
Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer

increase in serum estrogen levels, which is theoretically problematic in case of hormone-sensitive tumors such as breast cancer. The majority of oncology teams accept, in very specific situations

breast cancer
estrogen
adjuvant chemotherapy
follicle stimulating hormone
ductal carcinoma
  • 0 views
  • 26 Apr, 2021
  • 1 location
A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors

(MTD) of monotherapy. 2.To evaluate the safety and tolerability of LXI-15029 in Chinese postmenopausal patients with metastatic or locally advanced breast cancer with estrogen receptor (+) and human

erbb2
estrogen receptor
exemestane
epidermal growth factor
tumor cells
  • 18 views
  • 26 Jan, 2021
  • 1 location
Physiologic Changes of Posterior Ocular Segment During the Menstrual Cycle

Changes of luteinizing hormone (LH), estrogen and progesterone during the menstrual cycle influence the ocular physiology in both anterior and posterior segments. From the literature review

  • 0 views
  • 09 Jul, 2021
  • 1 location
Inositols and FSH in IVF

unusually elevated estrogen levels as both indicator for OHSS and one possible etiological factor. In this scenario, myo-inositol (MYO) treatment proved to reduce the amount of FSH units and the duration of

  • 0 views
  • 29 Jan, 2021
  • 1 location
Tamoxifen in Treating Patients With Metastatic Bladder Cancer That Did Not Respond to Previous Chemotherapy

RATIONALE: Tamoxifen may slow the growth of tumor cells and may be an effective treatment for patients with metastatic bladder cancer that did not respond to previous chemotherapy. PURPOSE: This phase II trial is studying how well tamoxifen works in treating patients with metastatic bladder cancer that did not respond …

tumor cells
  • 28 views
  • 07 Nov, 2020
  • 1 location
Postmenopausal Women and Their Endothelium

The purpose of this study is to test the effects of a one time dose of inorganic nitrate (supplied in the form of beetroot juice) on blood vessel function and resting blood pressure in healthy, postmenopausal women who are within 5 years of menopause. Participants will drink beetroot juice and …

  • 1 views
  • 26 Jan, 2021
  • 1 location
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+ HER2- Advanced Breast Cancer Patients (HERMIONE-7)

The HERMIONE-7 trial is a phase II, single-arm, open-label, multicenter study in HR+, HER2- advanced breast cancer patients who have received HD-FUL as first-line endocrine treatment for their metastatic disease. Patients will receive aromatase inhibitors plus Abemaciclib.

metastasis
HER2
her2-negative breast cancer
aromatase inhibitor
cish
  • 0 views
  • 19 Jul, 2021
  • 49 locations